Predict your next investment

HEALTHCARE | Drug Manufacturing
sxtchina.com

See what CB Insights has to offer

Founded Year

2005

Stage

IPO | IPO

Date of IPO

1/4/2019

Market Cap

0.00B

Stock Price

0.19

About China SXT Pharmaceuticals

China SXT Pharmaceuticals is a pharmaceutical company based focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.

China SXT Pharmaceuticals Headquarter Location

No.178 North Taidong Road

Taizhou, Jiangsu, 225300,

China

+86-523-8629-8290

Latest China SXT Pharmaceuticals News

China SXT Pharmaceuticals Stock (SXTC): Why The Price Substantially Went Down Today

Jan 18, 2022

The stock price of China SXT Pharmaceuticals Inc (NASDAQ: SXTC) fell by over 45% pre-market today. This is why it happened. The stock price of China SXT Pharmaceuticals Inc (NASDAQ: SXTC) – a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (TCMHS) – fell by over 45% pre-market today. Investors are responding negatively to China SXT Pharmaceuticals announcing that it intends to offer in an underwritten public offering its ordinary shares and prefunded warrants to purchase ordinary shares. These pre-funded warrants shall be offered at the same price per share as the ordinary shares, less the $0.0001 per share exercise price of each pre-funded warrant. And the company plans to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital and other business opportunities. This offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. And the base offering is expected to be up to approximately $3.4 million, and the underwriter will receive an overallotment option to purchase an additional 15% of the number of ordinary shares and/or pre-funded warrants sold for 45 days following the closing. Aegis Capital is acting as the sole book-running manager for the offering. Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

China SXT Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

China SXT Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.